Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease

NCT07078994 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

204

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease (CD)

Interventions

BIOLOGICAL: anti-TL1A monoclonal antibody, low dose
BIOLOGICAL: anti-TL1A monoclonal antibody, medium dose
BIOLOGICAL: anti-TL1A monoclonal antibody, high dose
OTHER: Placebo

Sponsor

Biocad